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Chemical carcinogens from cigarette smoking and occupational exposure are risk factors for bladder transitional cell carcinoma
(TCC). The Xeroderma Pigmentosum Group C (XPC) gene is essential for repair of bulky adducts from carcinogens. The Xeroderma
Pigmentosum Group C gene polymorphisms may alter DNA repair capacity (DRC), thus giving rise to genetic predisposition to
bladder cancer. Recent studies have demonstrated linkage disequilibrium between three polymorphisms in the XPC gene (polyAT,
IVS11-6 and Lys939Gln) and these have been shown to influence the DRC, as well as to be associated with bladder cancer risk. We
analysed all three XPC polymorphisms in 547 bladder TCC patients and 579 cancer-free controls to investigate the association
between these polymorphisms and bladder cancer susceptibility, and we also attempted to assess gene–environmental interactions.
We confirmed strong linkage disequilibrium among the polymorphisms (Lewontin’s D040.99). Using logistic regression adjusting for
smoking, occupational and family history, neither the heterozygote nor the homozygote variants of these polymorphisms were
associated with increased bladder cancer risk (adjusted odds ratio [95% confidence interval] for heterozygote 0.82 [0.63–1.07], 0.82
[0.63–1.08] and 0.83 [0.63–1.08] for PolyAT, IVS11-6 and Lys939Gln, respectively and homozygote variant, 0.98 [0.68–1.42], 0.99
[0.69–1.43] and 1.01 [0.70–1.46]). Moreover, we did not find any significant interaction between these XPC polymorphisms and
environmental exposure to cigarette smoking and occupational carcinogens.
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Transitional cell carcinoma (TCC) of the bladder is the fourth
commonest cancer in men and eighth in women in the USA and
UK (Greenlee et al, 2000; Office of National Statistics, 2000). The
two established risk factors for TCC are chemical carcinogens from
cigarette smoking and occupation exposure (Zeegers et al, 2000;
Kogevinas et al, 2003). Bulky DNA adducts formed by these
carcinogens are repaired by nucleotide excision repair (NER).
Failure to repair this DNA damage can cause mutations in
oncogenes and tumour suppressor genes resulting in tumour
formation. The xeroderma pigmentosum group C (XPC) protein
plays an important role in the initiation of this pathway.
Polymorphisms in the XPC gene may alter NER capacity, thus
giving rise to genetic predisposition to bladder cancer.
Recently, Khan et al (2000) discovered a common XPC polyAT
(XPC-PAT) polymorphism in intron 9, which involves deletion of
five base pairs (bp) and insertion of an 83bp AT repeat. The XPC-
PAT was found to be in strong linkage disequilibrium (LD) with
the XPC coding single-nucleotide polymorphism (SNP) Lys939Gln
in exon 15 and also an intronic SNP (IVS11-6) in intron 11 that
effects alternative splicing and hence alters protein function (Khan
et al, 2002). Although the abnormal splice variant resulted in
reduced DNA repair capacity (DRC) in vitro using an allele-
specific post-UV plasmid host cell reactivation assay (Khan et al,
2002), the variant XPC 939Gln allele was not associated with
reduced DRC (Khan et al, 2000). However, in a recent case–
control study, homozygotes for the 939Gln allele were found to
have a significantly increased risk of bladder cancer (Sanyal et al,
2004). In addition, the homozygous variant XPC-PAT insertion
(‘þ/þ’) has been associated with an increased risk of squamous
cell carcinoma of the head and neck (Shen et al, 2001), and in
lymphocytes from normal subjects homozygotes for XPC-PAT had
reduced DRC (Qiao et al, 2002).
We therefore hypothesised that the XPC polymorphisms XPC-
PAT, IVS11-6 and Lys939Gln have a role in the aetiology of TCC of
the bladder through modification of risk produced by smoking
and occupational exposure. We conducted a case–control study to
examine the LD between all three polymorphisms and their
association with bladder TCC risk. We also investigated gene–
environment interactions between the XPC polymorphisms and
smoking and occupational exposure to chemical carcinogens.
MATERIALS AND METHODS
Study population
Local ethical approval was obtained from the Leeds Teaching
Hospitals Local Research Ethics Committee (LREC) for this study.
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ing subjects.
In total, 626 patients were admitted to our institution for
bladder tumour surgery between August 2002 to April 2004.
Eligibility criteria for cases were patients with pathologically
confirmed TCC in the tumour specimen obtained from biopsy or
surgical resection, age more than 18 years and mental competence
to give informed consent. Exclusion criteria were patients with
non-TCC tumours (n¼46), mental incompetence such as demen-
tia (n¼6), patients who had had a blood transfusion less than 1
month before surgery (n¼23). In all, 92% of eligible patients were
recruited (547 patients out of 549 eligible subjects); only two
patients declined to participate in this study. Controls were
subjects who were cancer free and had no symptom of haematuria
(blood in urine). They were frequency matched by age and sex but
no attempt was made at one-to-one matching of cases and
controls. The controls (n¼579) were recruited from two sources:
community-based (n¼227) from a previous molecular epidemiol-
ogy study (Barrett et al, 2003), in the same region and hospital-
based (n¼352) from individuals who attended the ophthalmology
and otolaryngology clinics in the same institution. Overall, the
refusal rate of participation from the controls was approximately
20%. After informed consent was obtained, a blood specimen was
collected from each subject.
Data collection
Each subject underwent a 15–20min interview with investigators
and completed a structured health questionnaire regarding
smoking, occupation and family history. Smoking status was
recorded as nonsmoker, exsmoker or current smoker, and
smoking dose was measured in pack years. (One pack-year was
defined as smoking 20 cigarettes per day for 1 year or any pattern
leading to the same total exposure). Occupational exposure was
defined as participating in occupations involving the rubber
industry, the plastics industry, laboratories, printing, paints, dyes
or diesel fumes. Positive family history was defined as reporting
having any first- or second-degree relative diagnosed with bladder
cancer. Histopathological information regarding tumour stage and
grade was determined according to the TNM (tumour-nodes-
metastasis) staging system and data were obtained from patient
medical notes and the hospital pathology report.
Genotyping
Genomic DNA was extracted from blood samples collected from
patients with TCC and control subjects using the modified salt
precipitation method Puregene kit (Nottingham, UK) in the
Regional Genetics Laboratory, Leeds. The method of Khan et al
(2000) was used to amplify the XPC polyAT polymorphism.
We fluorescently labelled the forward primer used by Khan et al
to allow gel-free genotyping using a Genetic Analyser 3100
(Applied Biosystems, Foster City, CA, USA). Genotyping for SNP
Lys939Gln and IVS11-6 were performed in the Cancer Research
UK Genotyping Facility, Oxford, using the allelic discrimination
50 nuclease assay (Taqman) without prior knowledge of the
subject’s clinical status. Primer and probe sets were designed
and manufactured using Applied Biosystems ‘Assay-by-Design’
custom service (Applera, Austria). The primers and probe sets
used for Lys939Gln were: forwards primer (50AGCAGCTTCCCAC
CTGTTC 30), reverse primer (50 GTGGGTGCCCCTCTAGTG 30),
VIC probe (50 CTCACAGCTTCTCAAAT 30) and FAM probe (50
CACAGCTGCTCAAAT 30), and for IVS11-6 were forward primer
(50 GAGGTACACATTCCCAAACTCGTT 30), reverse primer (50
GCTGGCCAAATGCTGACTTG 30), VIC probe (50 CACCCGCCA
CAGGT 30) and FAM probe (50 TCACCCGACACAGGT 30). Each
PCR reaction was carried out in a 384-well MicroAmp optical plate
(ABI) using a total volume of 10ml containing 5mlo f2 Taqman
universal master mix, 20mM of sequence detection primers, 5mM of
allele-specific hybridisation probes and 10ng of genomic DNA.
Thermal cycling parameters were: 2min at 501 and 10min at 951
for primary denaturation, followed by 40 cycles of 15s at 951 and
1min at 601. Once the thermal cycling had been completed, the
plate was transferred to an Applied Biosystems 7900HT sequence
detection system and the fluorescence in each reaction was read.
Using the graphical view within the SDS software (ABI), each
group of alleles could be manually selected and each sample
designated as homozygous wild-type, heterozygous or homozy-
gous variant. As a quality control, 5% of the samples (n¼57) were
reanalysed, and results were identical for all samples (100%
concordance).
Statistical analysis
All data were analysed using STATA version 8 (StataCorp LP,
Texas). Hardy–Weinberg equilibrium analyses were performed to
compare observed and expected genotype frequencies using a chi-
squared goodness-of-fit test. The LD between polymorphisms was
estimated by pairwise Lewontin’s D0 using the STATA pwld
function (/http://www-gene.cimr.cam.ac.uk/clayton/S). The odds
ratio (OR) and 95% confidence interval (CI) for bladder cancer
associated with each genotype were calculated using logistic
regression analysis and were adjusted for established bladder
Table 1 Characteristics of study subjects
Risk factors Cases (%) Controls (%) P-value*
Age at interview (years)
p60 54 (13.0) 75 (9.9)
61–70 142 (24.3) 141 (26.0)
71–80 212 (39.0) 226 (38.7)
X80 139 (23.7) 137 (25.4) 0.4
Gender
Female 159 (29.1) 200 (34.5)
Male 388 (70.9) 379 (65.5) 0.05
Race
White 539 (98.5) 571(98.6)
Other 8 (1.5) 8 (1.4) 0.91
Smoking status
a
Never 121 (22.2) 195 (33.7)
Ex 293 (53.7) 288 (49.7)
Current 132 (24.1) 96 (16.6) o0.001
Number of years smoked
a
0 121 (22.2) 195 (33.7)
1–20 81 (14.8) 108 (18.6)
21–40 136 (24.9) 132 (22.8)
440 208 (38.1) 144 (24.9) o0.001
Number of pack-years
a
0 121 (22.2) 195 (33.7)
p25.5 195 (35.7) 202 (34.9)
425.5 216 (39.6) 176 (30.4)
Pipe smoker 14 (2.5) 6 (1.0) o0.001
Occupational exposure
No 397 (72.6) 482 (83.2)
Yes 150 (27.4) 97 (16.8) o0.001
Family history of bladder cancer
No 521 (95.2) 566 (97.8)
Yes 26 (4.8) 13 (2.2) 0.02
*All P-values were calculated by chi-squared testing of contingency tables.
aOne case
had inadequate smoking information.
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RESULTS
Subject characteristics
The demographic characteristics of the 547 cases and 579 controls
are shown in Table 1. The majority of the subjects (98.6%) were
Caucasian and 83.5% were born in the Yorkshire region, UK.
Despite attempts to match on sex, there were slightly more men in
the case group (71%) than the control group (65%). As expected,
the smoking prevalence among cases was higher than in controls.
Similarly, cases were more likely to have had occupational
exposure and a positive family history of bladder cancer compared
to controls (Po0.001 and 0.02, respectively).
XPC polymorphisms and the risk of bladder TCC
Overall, genotyping was successful in more than 98% of samples
(99.6, 97.9 and 97.1% for XPC-PAT, IVS11-6 and Lys939Gln,
respectively). The control genotype distribution for all three
polymorphisms was in Hardy–Weinberg equilibrium (P¼0.76,
0.63 and 0.67 for XPC-PAT, IVS11-6 and Lys939Gln, respectively).
We also compared the genotype distributions between the
community and the hospital controls and found no significant
difference in genotype distribution between the two control groups
(P¼0.18, 0.13, 0.12 for XPC-PAT, IVS11-6 and Lys939Gln,
respectively). Therefore, we combined the controls to increase
our power to detect an association between the polymorphisms
and bladder TCC risk. Among 1086 subjects with complete
genotypes for all three polymorphisms, the genotype distribution
and LD are shown in Table 2. The pairwise Lewontin’s D0 among
the three polymorphisms were all at least 0.99.
The frequencies of the XPC-PAT, IVS11-6 and Lys939Gln in
bladder TCC cases and the controls are shown in Table 3. To
evaluate the risk of bladder TCC according to genotype, logistic
regression analysis was conducted with an adjustment for age,
gender, smoking, occupation and family history of bladder cancer
(Table 3). There was no association between any of the three
polymorphisms and bladder TCC risk. We also analysed the
association of these polymorphisms in white subjects only, and the
result was very similar. None of the three polymorphisms were
significantly associated with increased bladder TCC risk (chi
square, P¼0.14, 0.17, 0.17 for XPC-PAT, IVS11-6 and Lys939Gln,
respectively). We also found no evidence of interactions between
the genotypes of any of the three polymorphisms and smoking
exposure or occupational exposure (P-value for departure from
multiplicative joint effect¼0.75 and 0.82 for smoking and
occupational exposure). We present data for XPC-PAT only as
results for the other two polymorphisms were very similar (Table 4
and data not shown).
DISCUSSION
To our knowledge, this is the largest case–control study of all
three polymorphisms of the XPC gene in bladder cancer, and it
involved an ethnically homogeneous population. With a sample
size of 547 cases and 579 controls, we had an 83% power (two-
sided test, P¼0.05) to detect an OR of 1.6 for the homozygote
variant compared with other genotypes. Our study was limited by
potential selection bias since we included both community and
hospital controls. However, the similarity of the genotype
distributions between the two control groups makes it unlikely
that the use of controls initially recruited for another study has
influenced our conclusions. We also cannot exclude any recall bias
for smoking and occupational exposure.
From our data, we observed no association between the three
XPC polymorphisms and bladder TCC risk. Sanyal et al, in a study
of 304 cases and 246 controls, estimated an OR of 1.97 (95% CI
1.10–3.57) for 939Gln/Gln homozygotes compared with those with
other genotypes. Although our study was larger and had sufficient
power to replicate this, we found no evidence to support the
finding of increased bladder cancer risk. This discrepancy could be
due to differences in the populations studied. Alternatively, the
earlier finding could be a false positive result. Wacholder et al
(2004) have shown that, unless the prior probability of an
Table 2 The association between XPC-PAT, IVS11-6 and Lys939Gln
among 1086 subjects
IVS 11-6
XPC-PAT C/C C/A A/A Lys939Gln
 /  394 0 0 A/A
0 3 0 A/C
0 0 0 C/C
 /+ 0 0 0 A/A
1 517 0 A/C
0 0 1 C/C
+/+ 0 0 0 A/A
0 1 0 A/C
0 0 169 C/C
Table 3 The association between the XPC polymorphisms (XPC-PAT, Lys939Gln and IVS11-6) and bladder TCC risk
Polymorphisms Genotypes Control
a (n) Cases
a (n) Crude OR (95% CI) Adjusted OR (95% CI) P-value
XPC-PAT  /  204 215 1.00 1.00
+/  288 242 0.80 (0.62–1.03) 0.82 (0.63–1.07) 0.15
+/+ 85 87 0.97 (0.68–1.38) 0.98 (0.68–1.42) 0.95
Lys939Gln A/A 192 204 1.00 1.00
A/C 285 241 0.80 (0.61–1.04) 0.82 (0.63–1.08) 0.14
C/C 84 87 0.97 (0.67–1.42) 0.99 (0.69–1.43) 0.97
IVS11-6 C/C 196 206 1.00 1.00
A/C 287 243 0.81 (0.62–1.04) 0.83 (0.63–1.08) 0.16
A/A 83 87 1.00 (0.70–1.43) 1.01 (0.70–1.46) 0.96
Adjusted OR: odds ratio adjusted for age, sex, smoking, occupational exposure and family history of bladder cancer; 95% CI¼95% confidence interval.
aThe total number of
cases and controls vary between polymorphisms because of failure of genotyping.
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showing marginal statistical significance in studies of low to
moderate power will be false positive results. Of interest, a recent
follow-up study of 288 superficial bladder cancer patients showed
no association between XPC-PAT or Lys939Gln variants and
increased risk of tumour recurrence (Gu et al, 2005).
We observed no interactions between the three XPC
polymorphisms and smoking or occupational exposure by
stratifying by smoking status (nonsmokers vs ex or current
smokers) and by occupational exposure (yes or no). However, our
study is unable to rule out more complex interactions with
environmental exposures.
In conclusion, we found the XPC polymorphisms XPC-PAT,
Lys939Gln and IVS11-6 to be in LD (D0X0.99), and none of the
polymorphisms was associated with increased risk of bladder TCC.
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